
    
      This is a Phase 1/2 single-arm, open-label, multicenter study evaluating the safety and
      efficacy of a single unit dose of EDIT-301 for autologous hematopoietic stem cell transplant
      (HSCT) in subjects with severe SCD. Planned study subjects will be comprised of male and
      female adult subjects with severe SCD, from 18 to 50 years of age, inclusive.
    
  